ClinicalTrials.Veeva

Menu

Productive Value of Sonographic Measurement of Optic Nerve in Transitional Multiple

A

Assiut University

Status

Not yet enrolling

Conditions

Relapsing Remitting Multiple Sclerosis

Treatments

Device: sonography

Study type

Observational

Funder types

Other

Identifiers

NCT06435962
optic nerve affection in RRMS

Details and patient eligibility

About

1.to evaluate the potential role of the optic nerve diameter ( OND determined by ultrasonography and and visual nerve function by visual evoked potential as a biomarker of early axonal loss and disability in patients with relapsing remitting multiple sclerosis (RRMS).

Full description

Multiple sclerosis (MS) is one of the leading disabling neurological diseases in young Adults. Characteristically reliable biomarkers for every independent MS pathogenic factor are extremely important.

1 Increasing evidence has demonstrated that neuronal and axonal damage within the central nervous system (CNS) contributes substantially to the development of permanent disability in patients with MS

  • 2 Thus, reliable, economic and easily assessable complementary surrogate biomarkers for axonal Degeneration and consequently disability remain to be identified
  • 3 The optic nerve can serve as a useful clinical tool for studying these characteristics and can be used to Measure and monitor the pathological process of the disease. The optic nerve is most commonly assessed by ophthalmoscopy and magnetic resonance imaging (MRI), But measurement of the optic nerve diameter (OND) by a simple ultrasound examination and measurement of optic nerve function by visual evoked potential might permit a rough estimation of the extent of brain parenchymal involvement and the consequent global cerebral atrophy and disability In relapsing-remitting MS (RRMS) patients.

The analysis of the diameter of the optic nerve showed that it is possible To detect its atrophy in the affected eyes (with optic neuritis ) and, to a lesser extent, in un affected eye Also the visual evoked potential study has the ability to quantify the unsuspected clinically silent lesions, hence, allows confirming the vague deterioration of visual functions.

Enrollment

100 estimated patients

Sex

All

Ages

15 to 50 years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

  1. inclusion criteria

    1. both sex
    2. Age group from 15 to 50 yrs
    3. Patient with RRMS without history of optic neuritis
  2. Exclusion criteria :

    1. History of previous optic neuritis
    2. Medical illness of eye(e.g. diabetes and hypertension)
    3. MS patient on fingolimod for 6 months or more
    4. Relapsing or use of steroid in the past 3 months
    5. Proved alternative diagnosis (neuromyelitis optica )
    6. local eye disease or surgery

Trial contacts and locations

0

Loading...

Central trial contact

Anwar M Ali, professor; Randa A Mohamed, resident

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems